Possible genesis of polycystic ovary syndrome in the periadolescent girl

Current Opinion in Endocrinology and Diabetes

Volumn 5, Issue 1, 1998, Pages 19-26

  Ibáñez, Lourdes ^a   Potau, Neus ^a   Carrascosa, Antonio ^a  

^a HOSPITAL MATERNO INFANTIL VALL D HEBRON   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; CYTOCHROME P450; INSULIN RECEPTOR; LUTEINIZING HORMONE; SEX HORMONE BINDING GLOBULIN; SOMATOMEDIN; SOMATOMEDIN BINDING PROTEIN 1;

ADOLESCENCE; ADOLESCENT; ANDROGEN SYNTHESIS; FEMALE; HUMAN; HYPERANDROGENISM; HYPERINSULINEMIA; LUTEINIZING HORMONE RELEASE; ONSET AGE; OVARY POLYCYSTIC DISEASE; PATHOGENESIS; PUBERTY; REVIEW;

EID: 0031923471     PISSN: 10683097     EISSN: None     Source Type: Journal    
DOI: 10.1097/00060793-199802000-00004     Document Type: Review

References (101)

1. Stein IF, Leventhal ML: Amenorrhea associated with bilateral polycystic ovaries. Am J Obstet Gynecol 1935, 29:181-191.
2. Yenn SSC, Vela P, Rankin J: Inappropriate secretion of follicle-stimulating hormone and luteinizing hormone in polycystic ovarian disease. J Clin Endocrinol Metab 1970, 30:435-442.
3. Hatch R, Rosenfield RL, Kim MH, Tredway D: Hirsutism: implications, etiology, and management. Am J Obstet Gynecol 1981, 140:815-830.
4. Goldzieher MW, Green JA: The polycystic ovary: I. Clinical and histologic features. J Clin Endocrinol Metab 1962, 22:325-338.
5. Zawadzki JK, Dunaif A: Diagnostic criteria for polycystic ovary syndrome: towards a rational approach. In Current Issues in Endocrinology and Metabolism: Polycystic Ovary Syndrome. Edited by Dunaif A, Givens JR, Haseltine FP, Merriam GR. Boston: Blackwell; 1992, 377-384.
6. Dunaif A, Segal DR, Shelley DR, Green G, Dobrjansky A, Licholai T: Evidence for distinctive and Intrinsic defects in Insulin action in polycystic ovary syndrome. Diabetes 1992, 41:1257-1266.
7. Ehrmann DA, Barnes RB, Rosenfield RL: Polycystic ovary syndrome as a form of functional ovarian hyperandrogenism due to dysregulation of androgen secretion. Endocr Rev 1995, 16:322-353.
8. Soulez B, Dewailly D, Rosenfield RL: Polycystic ovary syndrome: a multidisciplinary challenge. The Endocrinologist 1996, 6:19-29.
9. McKenna TJ: Current concepts: pathogenesis and treatment of polycystic ovary syndrome. N Engl J Med 1988, 318:558-562.
10. Chang RJ, Manfdel FP, Lu JK, Judd HL: Enhanced disparity of gonadotropin secretion by estrone in women with polycystic ovarian disease. J Clin Endocrinol Metab 1982, 54:490-494.
11. Hall JE: Polycystic ovarian disease as a neuroendocrine disorder of the female reproductive axis. Endocrinol Metab Clin North Am 1993, 22:75-92.
12. Waldstreicher J, Santoro N, Hall J, Filicori M, Crowley WF Jr: Hyperfunction of the hypothalamic-pituitary axis in women with polycystic ovarian disease: indirect evidence for partial gonadotropin desensitization. J Clin Endocrinol Metab 1988, 66:165-172.
13. Crowley WF Jr, Hall JE, Martin KA, Adams J, Taylor AE: An overview of the diagnostic considerations in polycystic ovarian syndrome. Ann N Y Acad Sci 1993, 687:235-241.
14. Barnes RB, Lobo RA: Central opioid activity in polycystic ovary syndrome with and without dopaminergic modulation. J Clin Endocrinol Metab 1985, 61:779-782.
15. Cumming DC, Reid RL, Quigley ME, Rebar RW, Yen SCC: Evidence for decreased endogenous dopamine and opioid inhibitory influences on LH secretion in polycystic ovary syndrome. Clin Endocrinol 1984, 20:643-648.
16. Homburg R: Polycystic ovary syndrome: from gynaecological curiosity • to multisystem endocrinopathy. Hum Reprod 1996, 11:29-39. This excellent review summarizes the recent progress in the understanding of the pathogenesis of PCOS, the diagnostic approaches, treatment, and long-term sequelae.
17. DeZiegler D, Steingold K, Cedars M, Lu JKH, Meldrum DR, Judd HL, Chang RJ: Recovery of hormone secretion after chronic gonadotropinreleasing hormone agonist administration in women with polycystic ovarian disease. J Clin Endocrinol Metab 1989, 68:1111-1117.
18. Barnes RB, Rosenfield RL, Burnstein S, Ehrmann DA: Pituitary-ovarian responses to nafarelin testing in the polycystic ovary syndrome. N Engl J Med 1989, 320:559-565.
19. Ehrmann DA, Rosenfield RL, Barnes RB, Brigell DF, Sheikh Z: Detection of functional ovarian hyperandrogenism In women with androgen excess. N Engl J Med 1992, 327:157-162.
20. Ibáñez L, Hall JE, Potau N, Carrascosa A, Prat N, Taylor AE: Ovarian 17-hydroxyprogesterone hyperresponsiveness to gonadotropin-releasing hormone (GnRH) agonist challenge in women with polycystic ovary syndrome is not mediated by luteinizing hormone hypersecretion: evidence from GnRH agonist and human chorionic gonadotropin stimulation testing. J Clin Endocrinol Metab 1996, 81:4103-4107.
21. Ibáñez L, Potau N, Zampolli M, Prat N, Gussinyé M, Saenger P, Vicens-Calvet E, Carrascosa A: Source localization of androgen excess in adolescent girls. J Clin Endocrinol Metab 1994, 79:1778-1784.
22. Ibáñez L, Potau N, Georgopoulos N, Prat N, Gussinyé M, Carrascosa A: Growth hormone, insulinlike growth factor-I axis, and insulin secretion in hyperandrogenic adolescents. Fertil Steril 1995, 64:1113-1119.
23. Ibáñez L, Potau N, Virdis R, Zampolli M, Terzi C, Gussinyé M, Carrascosa A, Vicens-Calvet E: Postpubertal outcome in girls diagnosed of premature pubarche during childhood: increased frequency of functional ovarian hyperandrogenism. J Clin Endocrinol Metab 1993, 76:1599-1603.
24. Morales AJ, Laughlin GA, Bützow T, Maheshwari H, Baumann G, Yen SSC: Insulin, somatotropic, and luteinizing hormone axes in lean and obese women with polycystic ovary syndrome: common and distinct features. J Clin Endocrinol Metab 1996, 81:2854-2864.
25. Dunaif A, Graf M, Mandeli J, Laumas V, Dobransky A: Characterization of groups of hyperandrogenic women with acanthosis nigricans, impaired glucose tolerance, and/or hyperinsullnemia. J Clin Endocrinol Metab 1987, 65:499-507.
26. Jialal I, Naiker P, Reddi K, Moodley J, Joubert SM: Evidence for Insulin resistance in nonobese patients with polycystic ovarian disease. J Clin Endocrinol Metab 1987, 64:1066-1069.
27. Dunaif A, Segal KR, Futterweit W, Dobrjansky A: Profound peripheral insulin resistance, independent of obesity, in the polycystic ovary syndrome. Diabetes 1989, 38:1165-1174.
28. Nestler JE, Clore JN, Blackard WG: The central role of obesity (hyperinsulinemla) in the pathogenesis of polycystic ovary syndrome. Am J Obstet Gynecol 1989, 161:1095-1097.
29. O'Meara NM, Blackman JD, Ehrmann DA, Barnes RB, Jaspan JB, Rosenfield RL, Polonsky KS: Defects in β-cell function In functional ovarian hyperandrogenism. J Clin Endocrinol Metab 1993, 76:1241-1247.
30. Ibáñez L, Potau N, Zampolli M, Prat N, Virdis R, Vicens-Calvet E, Carrascosa A: Hyperinsulinemia In postpubertal girls with a history of premature pubarche and functional ovarian hyperandrogenism. J Clin Endocrinol Metab 1996, 81:1237-1243.
31. Dunaif A: Hyperandrogenic anovulation (PCOS): a unique disorder of Insulin action associated with an increased risk of non-insulin-dependent diabetes. Am J Med 1995, 98 (suppl A):33S-39S.
32. Poretsky L: On the paradox of Insulin-induced hyperandrogenism in Insulin-resistant states. Endocr Rev 1991, 12:3-13.
33. Polderman KH, Gooren LJG, Asscheman H, Bakker A, Heine RJ: Induction of Insulin resistance by androgens and estrogens. J Clin Endocrinol Metab 1994, 50:113-116.
34. Dunaif A, Green G, Futterweit W, Dobrjansky A: Suppression of hyperandrogenism does not improve peripheral or hepatic insulin resistance In the polycystic ovary syndrome. J Clin Endocrinol Metab 1990, 70:699-707.
35. Elkind-Hirsch KE, Valdes CT, Malinak LR: Insulin resistance improves in hyperandrogenic women treated with Lupron. Fertil Steril 1993, 60:634-641.
36. Dunaif A: Insulin resistance and ovarian dysfunction. The Endocrinologist 1992, 2:248-260.
37. Barbieri RL, Makris A, Randall RW, Daniels G, Kistner RW, Ryan KJ: Insulin stimulates androgen accumulation in incubations of ovarian stroma obtained from women with hyperandrogenism. J Clin Endocrinol Metab 1986, 62:904-910.
38. Cara JF, Rosenfield RL: insulinlike growth factor I and insulin potentiate luteinizing hormone-induced androgen synthesis by rat ovarian thecal-interstitial cells. Endocrinology 1988, 123:733-739.
39. Poretsky L, Piper B: Insulin resistance, hypersecretion of LH, and a dual-defect hypothesis for the pathogenesis of polycystic ovary syndrome. Obstet Gynecol 1994, 84:613-621.
40. Suikkari AM, Koivisto VA, Rutanen EM, Yki-Järvinen H, Karonen SL, Seppäla M: Insulin regulates the serum levels of low molecular weight insulinlike growth factor binding protein. J Clin Endocrinol Metab 1988, 66:266-272.
41. Plymate SR, Matej LA, Jones RE, Friedl KE: Inhibition of sex hormone-binding globulin production in the human hepatoma (Hep G2) cell line by insulin and prolactin. J Clin Endocrinol Metab 1988, 67:460-464.
42. Nestler JE: Sex hormone-binding globulin: a marker for hyperinsulinemia and/or insulin resistance [editorial]? J Clin Endocrinol Metab 1993, 76:273-274.
43. Willis D, Mason H, Gilling-Smith C, Franks S: Modulation by insulin of follicle-stimulating hormone and luteinizing hormone actions in human granulosa cells of normal and polycystic ovaries. J Clin Endocrinol Metab 1996, 81:302-309.
44. Nestler JE, Barlascini CO, Matt DW: Suppression of serum insulin by diazoxide reduces serum testosterone levels in obese women with polycystic ovary syndrome. J Clin Endocrinol Metab 1989, 68:1027-1032.
45. Prelevic GM, Wurzburger MI, Balint-Peric L, Nesic JS: Inhibitory effect of sandostatin on secretion of luteinizing hormone and ovarian steroids in polycystic ovary syndrome. Lancet 1990, 336:900-903.
46. Velazquez EM, Mendoza S, Hamer T, Sosa F, Glueck CJ: Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy. Metabolism 1994, 43:647-654.
47. Nestler JE, Jakubowicz DJ: Decreases in ovarian cytochrome P450c17α activity and serum free testosterone after reduction of insulin secretion in polycystic ovary syndrome. N Engl J Med 1996, 335:617-623.
48. Dunaif A, Scott D, Finegood D, Quintana B, Whitcomb R: The insulin-sensitizing agent troglitazone improves metabolic and reproductive abnormalities in the polycystic ovary syndrome. J Clin Endocrinol Metab 1996, 81:3299-3306.
49. Ehrmann DA, Schneider DJ, Sobel BE, Cavaghan MK, Imperial J, • Rosenfield RL, Polonsky KS: Troglitazone improves defects in insulin action, insulin secretion, ovarian steroidogenesis, and fibrinolysis in women with polycystic ovary syndrome. J Clin Endocrinol Metab 1997, 82:2108-2116. This interesting study demonstrates that the administration of the insulin-sensitizing agent troglitazone to women with PCOS and impaired glucose tolerance results in a marked attenuation of hyperinsulinemia that is associated with improvements in insulin secretion, ovarian androgen biosynthesis, and enhanced fibrinolytic system capacity. These results are consistent with the hypothesis that insulin modulates the 17α-hydroxylase and 17,20-lyase activities of ovarian cytochrome P450c17α, further clarifying the pathogenetic role of insulin in PCOS, and suggest that troglitazone may be useful as an adjunct therapy.
50. Ehrmann DA, Cavaghan MK, Imperial J, Sturis J, Rosenfield RL, Polonsky • KS: Effects of metformin on insulin secretion, insulin action, and ovarian steroidogenesis in women with polycystic ovary syndrome. J Clin Endocrinol Metab 1997, 82:524-530. Metformin administration failed to diminish insulin resistance and hyperandrogenemia in a group of obese hyperinsulinemic women with PCOS, in whom weight loss was not achieved concomitantly. This study further supports the role of hyperinsulinemia in the pathogenesis of ovarian hyperandrogenism.
51. Crave JC, Fimbel S, Lejeune H, Cugnardey N, Dechaud H, Pugeat M: Effects of diet and metformin administration on sex hormone-binding globulin, androgens, and insulin in hirsute and obese women. J Clin Endocrinol Metab 1995, 80:2057-2062.
52. Jakubowicz DJ, Nestler JE: 17α-Hydroxyprogesterone responses to • leuprolide and serum androgens in obese women with and without polycystic ovary syndrome after dietary weight loss. J Clin Endocrinol Metab 1997, 82:556-560. The data of this study are consistent with the results obtained with troglitazone administration, ie, therapeutic measures directed at lowering insulin secretion, such as weight loss, ameliorate the hyperandrogenism in PCOS.
53. Rittmaster RS, Deshwasl N, Lehman L: The role of adrenal hyperandrogenism, insulin resistance, and obesity in the pathogenesis of polycystic ovarian syndrome. J Clin Endocrinol Metab 1993, 76:1295-1300.
54. Lucky AW, Rosenfield RL, McGuire J, Rudy S, Heike J: Adrenal androgen hyperresponsiveness to adrenocorticotropin in women with acne and/or hirsutism: adrenal enzyme defects and exaggerated adrenarche. J Clin Endocrinol Metab 1986, 62:840-848.
55. Loughlin T, Cunningham S, Moore A, Culliton M, Smyth PPA, McKenna TJ: Adrenal abnormalities in polycystic ovary syndrome. J Clin Endocrinol Metab 1986, 62:142-147.
56. Jakubowicz DJ, Beer NA, Beer RM, Nestler JE: Disparate effects of weight reduction by diet on serum dehydroepiandrosterone-sulfate levels in obese men and women. J Clin Endocrinol Metab 1995, 80:3373-3376.
57. Nestler JE, McClanahan MA, Clore JN, Blackard WG: Insulin inhibits adrenal 17,20 lyase activity in man. J Clin Endocrinol Metab 1992, 74:362-367.
58. L'Allemand D, Penhoat A, Lebrethon MC, Ardèvol R, Baehr V, Oelkers W, • Saez JM: insulinlike growth factors enhance steroidogenic enzyme and corticotropin receptor messenger ribonucleic acid levels and corticotropin steroidogenic responsiveness in cultured human adrenocortical cells. J Clin Endocrinol Metab 1996, 81:3892-3897. This article demonstrates the enhancing role of insulin and IGF-I and -II in corticotropin-stimulated steroidogenesis, suggesting a role for insulin in the pathogenesis of adrenal hyperandrogenism.
59. Mesiano S, Katz LS, Lee JY, Jaffe RB: insulinlike growth factors • augment steroid production and expression of steroidogenic enzymes in human fetal adrenal cortical cells: implications for adrenal androgen production. J Clin Endocrinol Metab 1997, 82:1390-1396. This study suggests that the activation of the type I IGF receptor on adrenal cortical cells may play a pivotal role in adrenal androgen production both physiologically in utero and at adrenarche, and in pathophysiologic conditions of hyperandrogenemia, such as PCOS.
60. Moghetti P, Castello R, Negri C, Tosi F, Spiazzi GG, Brun E, Balducci R, Toscano V, Muggeo M: Insulin infusion amplifies 17α-hydroxycorticosteroid intermediates response to adrenocorticotropin in hyperandrogenic women: apparent relative impairment of 17,20 lyase activity. J Clin Endocrinol Metab 1996, 81:881-886.
61. Rosenfield RL: Evidence that idiopathic functional adrenal hyperandrogenism is caused by dysregulation of adrenal steroidogenesis and that hyperinsulinemia may be involved [editorial]. J Clin Endocrinol Metab 1996, 81:878-880.
62. Miller WL: Molecular biology of steroid hormone synthesis. Endocr Rev 1988, 9:295-318.
63. Azziz R, Bradley EL, Potter D, Boots LR: Adrenal androgen excess in women: lack of a role for 17-hydroxylase and 17,20 lyase dysregulation. J Clin Endocrinol Metab 1995, 80:400-405.
64. Escobar-Morreale H, Serrano-Gotarredona J, Garcia-Robles R, Sancho JM, Varela C: Lack of an ovarian function influence on the increased adrenal androgen secretion present in women with functional ovarian hyperandrogenism. Fertil Steril 1997, 67:654-662.
65. Speiser PW, Serrat J, New MI, Gertner JM: Insulin sensitivity in adrenal hyperplasia due to non classical steroid 21-hydroxylase deficiency. J Clin Endocrinol Metab 1992, 75:1421-1424.
66. Legro RS: The genetics of polycystic ovary syndrome. Am J Med 1995, 98 (suppl 1A):9S-16S.
67. Lunde O, Magnus P, Sandvik L, Hoglo S: Familial clustering in the polycystic ovarian syndrome. Gynecol Obstet Invest 1989, 28:23-30.
68. Carey AH, Chan KL, Short F, White D, Williamson R, Franks S: Evidence for a single gene defect causing polycystic ovaries and male pattern baldness. Clin Endocrinol (Oxf) 1993, 38:653-658.
69. Jahanfar S, Eden JA, Warren P, Seppla M, Nguyen TV: A twin study of polycystic ovary syndrome. Fertil Steril 1995, 63:478-486.
70. Carey AH, Waterworth DM, Patel K, White D, Little J, Novelli P, Franks S, Williamson R: Polycystic ovaries and premature male pattern baldness are associated with one allele of the steroid metabolism gene CYP17. Hum Mol Genet 1994, 3:1873-1876.
71. Techatraisak K, Conway GS, Rumsby G: Frequency of a polymorphism in the regulatory region of the 17α-hydroxylase-17,20 lyase (CYP17) gene in hyperandrogenic states. Clin Endocrinol (Oxf) 1997, 46:131-134.
72. Gharani N, Waterworth DM, Batty S, White D, Gilling-Smith C, Conway GS, McCarthy M, Franks S, Williamson R: Association of the steroid synthesis gene CYP11a with polycystic ovary syndrome and hyperandrogenism. Hum Mol Genet 1997, 6:397-402.
73. Merrill JA: The morphology of the prepubertal ovary: relationship to the polycystic ovary syndrome. South Med J 1963, 56:225-231.
74. Rao JK, Chihal HJ, Johnson CM: Primary polycystic ovary syndrome in a premenarcheal girl: a case report J Reprod Med 1985, 30:361-365.
75. Feldman S, Billaud L, Thalabard JC, Raux-Demay MC, Mowszowicz I, Kuttenn F, Mauvais-Jarvis P: Fertility in women with late onset congenital adrenal hyperplasia due to 21-hydroxylase deficiency. J Clin Endocrinol Metab 1992, 74:635-639.
76. Barnes RB, Rosenfield RL, Ehrmann DA, Cara JF, Cuttler L, Levitsky LL, Rosenthal IM: Ovarian hyperandrogenism as a result of congenital adrenal virilizing disorders: evidence for perinatal masculinization of neuroendocrine function in women. J Clin Endocrinol Metab 1994, 79:1328-1333.
77. Penny R, Olambiwonnu ON, Fraiser SD: Episodic fluctuations of serum gonadotropins in pre- and postpubertal girls and boys. J Clin Endocrinol Metab 1977, 45:307-344.
78. Venturoli S, Porcu E, Fabbri R, Magrini O, Gammi L, Paradisi R, Flamigni C: Longitudinal evaluation of the different gonadotropin pulsatile patterns in anovulatory cycles of young girls. J Clin Endocrinol Metab 1992, 74:836-841.
79. Zumoff B, Freeman R, Coupey S, Saenger P, Markowitz M, Kream J: A chronobiologic abnormality in luteinizing hormone secretion in teenage girls with the polycystic ovary syndrome. N Engl J Med 1983, 309:1206-1209.
80. Apter D, Bützow T, Laughlin GA, Yen SCC: Accelerated 24-hour luteinizing hormone pulsatile activity in adolescent girls with ovarian hyperandrogenism: relevance to the developmental phase of polycystic ovarian syndrome. J Clin Endocrinol Metab 1994, 79:119-125.
81. Porcu E, Venturoli S, Longhi M, Fabbri R, Paradisi R, Flamigni C: •• Chronobiologic evolution of luteinizing hormone secretion in adolescence: developmental patterns and speculations on the onset of the polycystic ovary syndrome. Fertil Steril 1997, 67:842-848. This interesting article investigates the long-term evolution of the LH circadian profile in adolescents with anovulatory cycles and normal or elevated LH levels, and suggests that the persistence of the high LH circadian profiles characteristic of puberty in otherwise healthy anovulatory adolescents may herald the development of the typical PCOS pattern of LH hypersecretion, thus providing evidence for the peripubertal onset of this entity.
82. Root AW, Moshang F Jr: Evolution of the hyperandrogenism/polycystic ovarian syndrome from isosexual precocious puberty: report of two cases. Am J Obstet Gynecol 1984, 149:763-767.
83. Lazar L, Kauli R, Bruchis C, Nordenberg J, Galatzer A, Pertzelan A: Early polycystic ovary-like syndrome in girls with central precocious puberty and exaggerated adrenal response. Eur J Endocrinol 1995, 133:403-406.
84. Amiel SA, Caprio S, Sherwin RS, Plewe G, Haymond MW, Tamborlane WV: Insulin resistance of puberty: a defect restricted to peripheral glucose metabolism. J Clin Endocrinol Metab 1991, 72:277-282.
85. Caprio S. Plewe G, Diamond MP, Simonson DC, Boulware SD, Sherwin RS, Tamborlane WV: Increased insulin secretion in puberty: a compensatory response to reductions in insulin sensitivity. J Pediatr 1989, 114:963-967.
86. Potau N, Ibáñez L, Riqué S, Carrascosa A: Pubertal changes in insulin • secretion and peripheral insulin sensitivity. Horm Res 1997, 48:219-226. This article stresses that the state of insulin resistance characteristic of puberty is most evident at Tanner stage II, and is coincidental with the onset of gonadal secretion, a dramatic increase in IGF-I levels, and a marked decrease in sex hormone-binding globulin concentrations, thus supporting the established relationship among these parameters.
87. Holly JMP, Smith CP, Dunger DB, Howell RJS, Chard T, Perry LA, Savage MO, Cianfarani S, Rees LH, Wass JAH: Relationship between the pubertal fall in sex hormone binding globulin and insulinlike growth factor binding protein-1: a synchronized approach to pubertal development? Clin Endocrinol (Oxf) 1989, 31:277-284.
88. Nobels F, Dewailly D: Puberty and polycystic ovarian syndrome: the insulin/insulinlike growth factor hypothesis. Fertil Steril 1992, 58:655-666.
89. Apter D, Bützow T, Laughlin GA, Yen SSC: Metabolic features of polycystic ovary syndrome are found in adolescent girls with hyperandrogenism. J Clin Endocrinol Metab 1995, 80:2966-2973.
90. Ibáñez L, Virdis R, Potau N, Zampolli M, Ghizzoni L, Albisu MA, Carrascosa A, Bernasconi S, Vicens-Calvet E: Natural history of premature pubarche: an auxological study. J Clin Endocrinol Metab 1992, 74:254-257.
91. Korth-Schutz S, Levine LS, New MI: Evidence for the adrenal source of androgens in precocious adrenarche. Acta Endocrinol (Copenh) 1976, 82:242-252.
92. Ibáñez L, Bonnin MR, Zampolli M, Prat N, Alia PJ, Navarro MA: Usefulness of an ACTH test in the diagnosis of nonclassical 21-hydroxylase deficiency among children presenting with premature pubarche. Horm Res 1995, 44:51-56.
93. Ibáñez L, Potau N, Carrascosa A: Androgens in adrenarche and • pubarche. In Androgen Excess Disorders in Women. Edited by Azziz R, Nestler JE, Dewailly D. Philadelphia: Lippincott-Raven; 1997:73-84. This review emphasizes 1) the increased incidence of ovarian hyperandrogenism in premature pubarche due to premature adrenarche, a condition characterized by an early activation of adrenal androgen secretion, and 2) the apparent concurrence of adrenal and ovarian hyperandrogenism, supporting the hypothesis of dysregulation of adrenal and ovarian cytochrome P450c17α as a common pathogenetic link.
94. Temeck JW, Pang S, Nelson C, New MI: Genetic defects of steroidogenesis in premature pubarche. J Clin Endocrinol Metab 1987, 66:609-617.
95. Ibáñez L, Potau N, Zampolli M, Sreet ME, Carrascosa A: Girls diagnosed • with premature pubarche show an exaggerated ovarian androgen synthesis from the early stages of puberty: evidence from gonadotropin-releasing hormone agonist testing. Fertil Steril 1997, 67:849-855. This study demonstrates the pubertal onset of ovarian androgen hyperresponsiveness in girls with a history of premature pubarche, supporting the hypothesis that dysregulation of ovarian androgen secretion may be detectable in early puberty.
96. Ibáñez L, Potau N, Zampolli M, Marcos MV, Carrascosa A: Functional adrenal hyperandrogenism is a common feature In postpubertal girls with a history of premature pubarche: relationship to hyperinsulinemia and ovarian androgen excess [abstract]. Horm Res 1997, 48(suppl 2): 110.
97. Oppenheimer E, Under B, DiMartino-Nardi J: Decreased insulin sensitivity in prepubertal girls with premature adrenarche and acanthosis nigricans. J Clin Endocrinol Metab 1995, 80:614-618.
98. Ibáñez L, Potau N, Zampolli M, Riqué S, Saengar P, Carrascosa A: • Hyperinsulinemia and decreased insulin like growth factor-binding protein-1 are common features in prepubertal and pubertal girls with a history of premature pubarche. J Clin Endocrinol Metab 1997, 82:2283-2288. This study demonstrates that hyperinsulinemia and decreased IGF binding protein-1 and sex hormone-binding globulin concentrations are already present before puberty and throughout all stages of pubertal development in girls with a history of premature pubarche, a cohort with a well-known increased incidence of ovarian hyperandrogenism. These data suggest a common pathogenetic link between hyperinsulinemia and adrenal-ovarian androgen excess and points toward a peripubertal onset of these disorders.
99. Ibáñez L, Chacón P, Potau N, López D, Gussinyé M, Carrascosa A: Lipid patterns and their relation to insulin levels in girls with a history of premature pubarche [abstract]. Horm Res 1996, 46(suppl 2):88.
100. Zhang L, Rodriguez H, Ohno S, Miller WL: Serine phosphorylation of human P450c17 increases 17,20 lyase activity: implications for adrenarche and the polycystic ovary syndrome. Proc Natl Acad Sci U S A 1995, 92:10619-10623.
101. Miller WL: Pathophysiology, genetics and treatment of hyperandro•• genism. Pediatr Clin North Am 1997, 44:375-395. This interesting review examines the role of increased serine phosphorylation of adrenal and ovarian cytochrome P450c17α and increased serine phosphorylation of the insulin receptor in the pathogenesis of the three principal features of PCOS. According to this theory, adrenal hyperandrogenism and hyperinsulinemia would be present before the pubertal period, and would herald the development of ovarian hyperandrogenism when the activation of the hypothalamic-pituitary-gonadal axis occurs.